Stephen Wargacki's most recent trade in Aquestive Therapeutics Inc was a trade of 115,000 Common Stock done . Disclosure was reported to the exchange on March 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics Inc | Stephen Wargacki | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 115,000 | 376,414 (1%) | 0% | 0 | Common Stock | |
| Aquestive Therapeutics Inc | Stephen Wargacki | Chief Science Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 65,000 | 65,000 | - | - | Non-Qualified Stock Option (right to buy) | |
| Aquestive Therapeutics Inc | Stephen Wargacki | Chief Science Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.65 per share. | 07 Mar 2025 | 15,431 | 348,124 (1%) | 0% | 2.6 | 40,892 | Common Stock |
| Aquestive Therapeutics Inc | Stephen Wargacki | Chief Science Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.65 per share. | 07 Mar 2025 | 12,859 | 363,555 (1%) | 0% | 2.6 | 34,076 | Common Stock |
| Aquestive Therapeutics Inc | Stephen Wargacki | Chief Science Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.54 per share. | 07 Mar 2025 | 4,572 | 343,552 (1%) | 0% | 2.5 | 11,613 | Common Stock |
| Aquestive Therapeutics Inc | Stephen Wargacki | Chief Science Officer | 10 May 2024 | 10,000 | 267,963 (0%) | 0% | 0 | Common Stock | ||
| Aquestive Therapeutics Inc | Stephen Wargacki | Chief Science Officer | 09 Mar 2024 | 19,505 | 261,414 (0%) | 0% | 4.9 | 95,184 | Common Stock | |
| Aquestive Therapeutics Inc | Stephen Wargacki | SVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.88 per share. | 09 Mar 2024 | 11,269 | 259,650 (0%) | 0% | 4.9 | 54,993 | Common Stock |
| Aquestive Therapeutics Inc | Stephen Wargacki | SVP, Research & Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.88 per share. | 09 Mar 2024 | 1,687 | 257,963 (0%) | 0% | 4.9 | 8,233 | Common Stock |
| Aquestive Therapeutics Inc | Stephen Wargacki | SVP, Research & Development | 09 Aug 2023 | 67,500 | 67,500 | - | - | Performance Stock Units | ||
| Aquestive Therapeutics Inc | Stephen Wargacki | SVP, Research & Development | 05 May 2023 | 67,500 | 67,500 | - | - | Performance Stock Units | ||
| Aquestive Therapeutics Inc | Stephen Wargacki | SVP, Research & Development | 10 Mar 2023 | 112,500 | 270,919 (0%) | 0% | 0 | Common Stock | ||
| Aquestive Therapeutics Inc | Stephen Wargacki | SVP, Research & Development | 10 Mar 2023 | 56,250 | 56,250 | - | - | Non-Qualified Stock Option (right to buy) | ||
| Aquestive Therapeutics Inc | Stephen Wargacki | SVP, Research & Development | 10 Mar 2023 | 1,981 | 158,419 (0%) | 0% | 0.8 | 1,572 | Common Stock | |
| Aquestive Therapeutics Inc | Stephen Wargacki | SVP, Research & Development | 09 Mar 2023 | 135,000 | 161,956 (0%) | 0% | 0 | Common Stock |